임상 마이크로바이옴 진단 시장 규모, 점유율 및 동향 분석 보고서 : 제품 유형별, 기술별, 용도별, 검체 유형별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Clinical Microbiome Diagnostics Market Summary

The global clinical microbiome diagnostics market size was valued at USD 172.4 million in 2025 and is projected to grow from USD 195.7 million in 2026 to USD 500.8 million by 2033, at a CAGR of 14.4% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 40.3% in 2025. Market growth is primarily driven by technological advancements in sequencing and bioinformatics, which are improving the accuracy, speed, and scalability of microbial profiling and data interpretation.

Global Clinical Microbiome Diagnostics Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global clinical microbiome diagnostics market report on the basis of product, technology, application, sample type, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Diagnostic Tests & Assays
• Diagnostic Testing Services
• Diagnostic Software & Analysis
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Sequencing-Based
• PCR-Based
• Mass Spectrometry-Based
• Other Technologies
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Gastrointestinal Disorders
• Infectious Diseases
• Women's Health
• Metabolic Disorders
• Immune & Inflammatory Disorders
• Neurological Disorders
• Other Clinical Disorders
• Sample Type Outlook (Revenue, USD Million, 2021 - 2033)
• Gut
• Oral
• Vaginal
• Skin
• Respiratory
• Other Sites
• End use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Diagnostic Laboratories
• Direct-to-Consumer
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product Segment
  • 1.2.2. Technology Segment
  • 1.2.3. Application Segment
  • 1.2.4. Sample Type Segment
  • 1.2.5. End use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Infectious Disease Diagnostics
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Global Clinical Microbiome Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growing prevalence of gastrointestinal and microbiome-associated disorders
    • 3.2.1.2. Advancements in sequencing and molecular technologies
    • 3.2.1.3. Increasing adoption of precision medicine
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Lack of standardization in testing methodologies
    • 3.2.2.2. Limited clinical validation and utility
    • 3.2.2.3. Complexity of microbiome data interpretation
  • 3.2.3. Market opportunity analysis
• 3.3. Global Clinical Microbiome Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTLE Analysis

Chapter 4. Global Clinical Microbiome Diagnostics Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Clinical Microbiome Diagnostics Market Product Movement Analysis
• 4.3. Global Clinical Microbiome Diagnostics Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Diagnostic Tests & Assays
  • 4.4.1. Diagnostic Tests & Assays market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Diagnostic Testing Services
  • 4.5.1. Diagnostic Testing Services market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Diagnostic Software & Analysis
  • 4.6.1. Diagnostic Software & Analysis market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Global Clinical Microbiome Diagnostics Market: Technology Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Clinical Microbiome Diagnostics Market Technology Movement Analysis
  • 5.2.1. Global Clinical Microbiome Diagnostics Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
• 5.3. Sequencing-Based
  • 5.3.1. Sequencing-Based market estimates and forecasts 2021 to 2033 (USD Million)
• 5.4. PCR-BASED
  • 5.4.1. PCR-BASED market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Mass Spectrometry-Based
  • 5.5.1. Mass Spectrometry-Based market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Other Technologies
  • 5.6.1. Other Technologies market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Global Clinical Microbiome Diagnostics Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Clinical Microbiome Diagnostics Market Application Movement Analysis
  • 6.2.1. Global AI-enabled clinical laboratory analyzer Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.3. Gastrointestinal Disorders
  • 6.3.1. Gastrointestinal Disorders market estimates and forecasts 2021 to 2033 (USD Million)
• 6.4. Infectious Diseases
  • 6.4.1. Infectious Diseases market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Oncology
  • 6.5.1. Oncology market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Women's Health
• 6.7. Women's Health market estimates and forecasts 2021 to 2033 (USD Million)
• 6.8. Metabolic Disorders
  • 6.8.1. Metabolic Disorders market estimates and forecasts 2021 to 2033 (USD Million)
• 6.9. Immune & Inflammatory Disorders
  • 6.9.1. Immune & Inflammatory Disorders market estimates and forecasts 2021 to 2033 (USD Million)
• 6.10. Neurological Disorders
  • 6.10.1. Neurological Disorders market estimates and forecasts 2021 to 2033 (USD Million)
• 6.11. Other Clinical Disorders
  • 6.11.1. Other Clinical Disorders market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Global Clinical Microbiome Diagnostics Market: Sample Type Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Clinical Microbiome Diagnostics Market Sample Type Movement Analysis
  • 7.2.1. Global AI-enabled clinical laboratory analyzer Market Size & Trend Analysis, by Sample Type, 2021 to 2033 (USD Million)
• 7.3. Gut
  • 7.3.1. Gut market estimates and forecasts 2021 to 2033 (USD Million)
• 7.4. Oral
  • 7.4.1. Oral market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Vaginal
  • 7.5.1. Vaginal market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Skin
• 7.7. Skin market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. Respiratory
  • 7.8.1. Respiratory market estimates and forecasts 2021 to 2033 (USD Million)
• 7.9. Other Sites
  • 7.9.1. Other Sites market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Global Clinical Microbiome Diagnostics Market: End use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Clinical Microbiome Diagnostics Market End use Movement Analysis
  • 8.2.1. Global AI-enabled clinical laboratory analyzer Market Size & Trend Analysis, by End use, 2021 to 2033 (USD Million)
• 8.3. Hospitals & Clinics
  • 8.3.1. Hospitals & Clinics market estimates and forecasts 2021 to 2033 (USD Million)
• 8.4. Diagnostic Laboratories
  • 8.4.1. Diagnostic Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Direct-to-Consumer
  • 8.5.1. Direct-to-Consumer market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Clinical Microbiome Diagnostics Market: Regional Estimates & Trend Analysis

• 9.1. Regional Dashboard
• 9.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 9.3. North America
  • 9.3.1. U.S.
    • 9.3.1.1. Key country dynamics
    • 9.3.1.2. Regulatory framework/ reimbursement structure
    • 9.3.1.3. Competitive scenario
    • 9.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.3.2. Canada
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework/ reimbursement structure
    • 9.3.2.3. Competitive scenario
    • 9.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.3.3. Mexico
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Regulatory framework/ reimbursement structure
    • 9.3.3.3. Competitive scenario
    • 9.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 9.4. Europe
  • 9.4.1. UK
    • 9.4.1.1. Key country dynamics
    • 9.4.1.2. Regulatory framework/ reimbursement structure
    • 9.4.1.3. Competitive scenario
    • 9.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework/ reimbursement structure
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.3. France
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework/ reimbursement structure
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.4. Italy
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework/ reimbursement structure
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.5. Spain
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework/ reimbursement structure
    • 9.4.5.3. Competitive scenario
    • 9.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.6. Norway
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework/ reimbursement structure
    • 9.4.6.3. Competitive scenario
    • 9.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.7. Sweden
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Regulatory framework/ reimbursement structure
    • 9.4.7.3. Competitive scenario
    • 9.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.8. Denmark
    • 9.4.8.1. Key country dynamics
    • 9.4.8.2. Regulatory framework/ reimbursement structure
    • 9.4.8.3. Competitive scenario
    • 9.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Japan
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/ reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.2. China
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/ reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.3. India
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework/ reimbursement structure
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.4. Australia
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework/ reimbursement structure
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework/ reimbursement structure
    • 9.5.5.3. Competitive scenario
    • 9.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.6. Thailand
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework/ reimbursement structure
    • 9.5.6.3. Competitive scenario
    • 9.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 9.6. Latin America
  • 9.6.1. Brazil
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/ reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.2. Argentina
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/ reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 9.7. MEA
  • 9.7.1. South Africa
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/ reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/ reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.7.3. UAE
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/ reimbursement structure
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.7.4. Kuwait
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/ reimbursement structure
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company/Competition Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Share Analysis, 2025
• 10.4. List of Key Certification Providers/Scheme Owners
• 10.5. Company Profiles/Listing
  • 10.5.1. Microba Life Sciences
    • 10.5.1.1. Company overview
    • 10.5.1.2. Financial performance
    • 10.5.1.3. Product benchmarking
    • 10.5.1.4. Strategic initiatives
  • 10.5.2. Genetic Analysis AS
    • 10.5.2.1. Company overview
    • 10.5.2.2. Financial performance
    • 10.5.2.3. Product benchmarking
    • 10.5.2.4. Strategic initiatives
  • 10.5.3. Genova Diagnostics
    • 10.5.3.1. Company overview
    • 10.5.3.2. Financial performance
    • 10.5.3.3. Product benchmarking
    • 10.5.3.4. Strategic initiatives
  • 10.5.4. Viome
    • 10.5.4.1. Company overview
    • 10.5.4.2. Financial performance
    • 10.5.4.3. Product benchmarking
    • 10.5.4.4. Strategic initiatives
  • 10.5.5. Evvy
    • 10.5.5.1. Company overview
    • 10.5.5.2. Financial performance
    • 10.5.5.3. Product benchmarking
    • 10.5.5.4. Strategic initiatives
  • 10.5.6. Tiny Health
    • 10.5.6.1. Company overview
    • 10.5.6.2. Financial performance
    • 10.5.6.3. Product benchmarking
    • 10.5.6.4. Strategic initiatives
  • 10.5.7. Jona Health
    • 10.5.7.1. Company overview
    • 10.5.7.2. Financial performance
    • 10.5.7.3. Product benchmarking
    • 10.5.7.4. Strategic initiatives
  • 10.5.8. Sun Genomics
    • 10.5.8.1. Company overview
    • 10.5.8.2. Financial performance
    • 10.5.8.3. Product benchmarking
    • 10.5.8.4. Strategic initiatives
  • 10.5.9. BIOHM Health
    • 10.5.9.1. Company overview
    • 10.5.9.2. Financial performance
    • 10.5.9.3. Product benchmarking
    • 10.5.9.4. Strategic initiatives
  • 10.5.10. GoodGut
    • 10.5.10.1. Company overview
    • 10.5.10.2. Financial performance
    • 10.5.10.3. Product benchmarking
    • 10.5.10.4. Strategic initiatives